U.S. markets closed
  • S&P 500

    3,443.12
    +16.20 (+0.47%)
     
  • Dow 30

    28,308.79
    +113.37 (+0.40%)
     
  • Nasdaq

    11,516.49
    +37.61 (+0.33%)
     
  • Russell 2000

    1,617.71
    +4.08 (+0.25%)
     
  • Crude Oil

    41.51
    +0.68 (+1.67%)
     
  • Gold

    1,912.80
    +1.10 (+0.06%)
     
  • Silver

    24.88
    +0.18 (+0.72%)
     
  • EUR/USD

    1.1830
    +0.0057 (+0.49%)
     
  • 10-Yr Bond

    0.7970
    +0.0360 (+4.73%)
     
  • GBP/USD

    1.2942
    +0.0001 (+0.01%)
     
  • USD/JPY

    105.4700
    +0.0400 (+0.04%)
     
  • BTC-USD

    11,891.24
    +834.23 (+7.54%)
     
  • CMC Crypto 200

    239.12
    +0.20 (+0.08%)
     
  • FTSE 100

    5,889.22
    +4.57 (+0.08%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of MYOS RENS Technology Inc. with MedAvail, Inc. is Fair to MYOS Shareholders

Newsfile Corp.
·2 mins read

New York, New York--(Newsfile Corp. - July 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:



To: All Persons or Entities who purchased MYOS RENS Technology Inc. (NASDAQ: MYOS) ("MYOS RENS" or the "Company") stock prior to June 30, 2020.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of MYOS RENS with MedAvail, Inc. ("MedAvail"). Under the terms of the merger, a wholly-owned subsidiary of MYOS RENS will merge with and into MedAvail, with MedAvail being the surviving corporation and a wholly-owned subsidiary of MYOS RENS. Following the merger, MYOS RENS shareholders will own approximately 3.5% of the combined company and MedAvail's security holders and new investors will own approximately 96.5% of the combined company (on a fully diluted basis). To learn more about the action and your rights, go to:

https://www.zlk.com/mna2/myos-rens-technology-inc-information-request-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The MYOS RENS merger investigation concerns whether the Board of MYOS RENS breached their fiduciary duties to stockholders by agreeing to enter into this transaction and whether the merger undervalues MYOS RENS relative to MedAvail, thereby harming MYOS RENS shareholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59040